4月14日 - ** 辉瑞PFE.N称已停止开发试验性减肥药danuglipron (link) 之后，肥胖症制药商的股票在盘前交易中上涨
** 礼来LLY.N股价在盘前交易中上涨1.69%，至744.82美元；在美国上市的丹麦制药商诺和诺德NOVOb.CO股价上涨3.74%，至67.15美元。
** 肥胖症药物开发商Viking Therapeutics VKTX.O股价大涨19.1%，至26.47美元；Altimmune ALT.O上涨2.95%，至4.54美元。
** 辉瑞股价在收盘前小幅下跌，报 21.75 美元
** 截至上次收盘，LLY 下跌 ~5%，VKTX 下跌 ~45%，而 ALT YTD 下跌 39
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.